Pembrolizumab for hepatocellular carcinoma and lung cancer indications

Share This Post

Approval accelerated approval of pembrolizumab (Keytruda, Merck) for the treatment of patients with hepatocellular carcinoma (HCC) who had previously received sorafenib (Nexavar, Bayer). Keytruda is also approved in combination with carboplatin and paclitaxel or nab-paclitaxel for first-line treatment of metastatic squamous non-small cell lung cancer.

 

FDA is based on single-arm, open label KEYNOTE-224 test results. The trial included 104 patients (median age, 68 years; 83% males; 81% whites; 14% Asians) with HCC who experienced disease progression or against Intolerance. The ECOG performance status of all patients was 0 (61%) or 1 (39%), which was Child-Pugh grade A liver function impairment. In addition, 21% were seropositive for hepatitis B virus, 25% were seropositive for hepatitis C virus, and 9% were seropositive. 64% of patients have extrahepatic disease, 17% have vascular invasion, and 9% have both. Patients received pembrolizumab 200 mg every 3 weeks for 24 months, or until disease progression or unacceptable toxicity. Objective response rate and duration of response were used as the main efficacy results. The median exposure time of pembrolizumab was 4.2 months. The ORR reported by the researchers was 17% (95% CI, 11-26), including a 1% complete response rate and a 16% partial response rate. Of the 18 patients who obtained the response, 16 (89%) were still effective for at least 6 months, and 10 (56%) were still effective for at least 12 months.

The adverse effects of Pembrolizumab-treated HCC patients appeared to be similar to those observed in other studies of melanoma or NSCLC, but the incidence of ascites increased (grade 3/4, 8%) and immune-mediated hepatitis (2.9%). Grade 3 or 4 laboratory abnormalities that occurred more frequently in the KEYNOTE-224 trial included elevated alanine aminotransferase (20%), elevated aspartate aminotransferase (9%) and hyperbilirubinemia (10 %).

Keytruda’s approval provides a new treatment option for patients with hepatocellular carcinoma who have received sorafenib treatment.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy